Page 1

● ● PRESS RELEASE immatics Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update ACTengine® patient recruitment remains on track ; as of end of July , a total of 27 patients have been treated with IMA201 , IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof - of - concept for second TCER® molecule IMA402 Cash and cash equivalents as well as Other financial assets of $ 229.1 million¹ ( € 192.8 million ) as of June 30 , 2021 , funding company operations into 2023 Tuebingen , Germany and Houston , TX , August 10 , 2021 Immatics N.V. ( NASDAQ : IMTX ; “ Immatics ” ) , a clinical - stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies , today reported its financial results for the quarter ended June 30 , 2021 and provided a business update on its progress over the reporting period . " An important development during the second quarter of 2021 was a significant increase in patient enrollment for our ACTengine® programs , " said Harpreet Singh , Ph.D. , CEO of Immatics . " Following the positive initial results we provided in the first quarter , we now look forward to announcing more advanced data including safety , biological activity and the assessment of anti tumor activity for a range of different cancer indications in the second half of 2021. " " In addition to the upcoming clinical data for our ACTengine® trials , we are excited to move our second therapeutic modality towards the clinic , " added Carsten Reinhardt , M.D. , Ph.D. , Chief Development Officer at Immatics . " We are encouraged by the entirety of the IMA401 data set , which following discussions with regulatory authorities puts us in a strong position to submit our IMA401 Clinical Trial Application during the fourth quarter of 2021. Our TCER® pipeline is further strengthened by our second TCR Bispecifics program , IMA402 , for which we recently presented preclinical proof - of - concept data . " Second Quarter 2021 and Subsequent Company Progress Immatics Press Release August 10 , 2021 Adoptive Cell Therapy Programs ACTengine® IMA200 series Patient recruitment remains on track and the additional trial sites initiated in Europe and the US have supported the acceleration of recruitment . As of end of July , 27 patients have been treated in the IMA200 series . The first - in - human basket trials for IMA201 , IMA202 and IMA203 include patients with recurrent and / or refractory solid 1 | 10